The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2205    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Systemic/Surgery Sequence:  The note associated with code 4 in Systemic Treatment/Surgery Sequence in the 2018 SEER Manual says: Code 4 is intended for situations with at least two episodes or courses of systemic therapy.  Does this mean two different types of systemic therapy before and after surgery? See Discussion.

Final Jul 01 2020

2018 EOD Primary Tumor/2018 EOD Mets--Lung:  Is EOD Primary Tumor coded to 500 and EOD Mets 10 when there are bilateral lung nodules with nodules in same lobe as the primary tumor?  How is EOD Primary Tumor coded when separate tumor nodes are in an ipsilateral lung but there is no documentation as to whether it is in the same or different ipsilateral lobe from the primary tumor?

Final Jun 30 2020

Reportability--Ambiguous Terminology: Should either of the terms, strongly characteristic of or most certainly, be used to accession a case as reportable when they are used to describe a malignancy and no other information is available? See Discussion.

Final Jun 24 2020

EOD 2018--Lung: How should EOD Primary Tumor be coded when imaging describes a large left upper lobe 9.1 cm mass that traverses the left major fissure. Also noted is no pleural effusion and normal chest wall. See Discussion.

Final Jun 24 2020

Reportability/Ambiguous terminology--Bone: Is a case reportable when the imaging described a left first rib mass as most compatible with a chondroid lesion such as a chondrosarcoma? See Discussion.


Final Jun 24 2020

Reportability/Histology--Fallopian tube:  Is germ cell neoplasia in situ reportable? If so, is the histology and behavior 9064/2? See Discussion.

Final Jun 24 2020

Solid Tumor Rules (2018)/Histology--Endometrium:  Is the histology for a serous carcinoma, high-grade endometrial primary 8441/3 (serous carcinoma) or 8461/3 (high grade serous carcinoma)? See Discussion.

Final May 29 2020

Solid Tumor Rules (2018)/Multiple primaries--Breast: How many primaries should be reported for a December 2013 diagnosis of lobular carcinoma in situ (8520/2) in the left breast, treated with a lumpectomy, followed by a July 2018 diagnosis of invasive ductal carcinoma (8500/3) also in the left breast? See Discussion.

Final May 27 2020

Solid Tumor Rules/Histology--Head & Neck:  What is the histology of human papillomavirus (HPV)--associated multiphenotypic carcinoma? See Discussion.

Final May 26 2020

Reportability/Brain and CNS--Pituitary: Can a clinical diagnosis of pituitary adenoma be accessioned based on imaging if treatment is not given and subsequent imaging years later shows no evidence of pituitary adenoma? See Discussion.


Final May 21 2020
< Prev 10    Next 10 >